Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Lymphoma: chemotherapy vs. bendamustine

Mathias Rummel • 20 Jun 2017
ASCO 2017
Non-Hodgkin Lymphoma Bendamustine Rituximab

Mathias Rummel, MD, PhD from Justus Liebig University, Giessen, Germany presents the results of a long-term study initiated comparing CHOP-rituximab (CHOP-R) therapy to the combined therapy of bendamustine and rituximab in patients with lymphoma. The study showed that progression-free survival (PFS) was better in the bendamustine arm. The data presented at ASCO 2017 included mature overall survival (OS) data with a median of 10 years follow-up.
Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.

More from Mathias Rummel

StiL NHL7 MAINTAIN results shed light on B-R upfront and R-maintenance
4:55
StiL NHL7 MAINTAIN results shed light on B-R upfront and R-maintenance
Mathias Rummel • 7 Dec 2019
Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
2:43
Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Mathias Rummel • 21 Jun 2017
Investigating alternative treatments for non-reponsive lymphoma patients
1:16
Investigating alternative treatments for non-reponsive lymphoma patients
Mathias Rummel • 20 Jun 2017
Bendamustine for the treatment of non-Hodgkin lymphoma
7:50
Bendamustine for the treatment of non-Hodgkin lymphoma
Mathias Rummel • 5 Sep 2014

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals